Abstract: ObjectiveTo systemically review the efficacy and safety of magnesium sulfate for chronic obstructive pulmonary disease (CODP). MethodsThe randomized controlled trials (RCT) concerning magnesium sulfate for CODP from databases as Pubmed， Cochrane Library， Embase， CBM， CNKI， VIP， Chinese Medical Journal Digital and ISI Web of Knowledge published between inception to February 2015 were retrieved. Meta analysis on the selected literature was conducted by means of RevMan 5.0 software. Two reviewers screened literature according to the inclusion and exclusion criteria， extract data and assessed methodological quality of included studies. ResultsA total of 14 RCTs involving 955 patients were included.  Compared with control group， Magnesium sulfate had higher remission rate of clinical signs (OR=3.22， 95%CI=1.87 to 5.55，P<0.01)，higher FEV1%（MD=10.17， 95%CI=9.07 to 11.18，P<0.01）. However， compared with control group， magnesium sulfate had no significant differences in FEV1 (MD=0.05，95%CI=0.00 to 0.10，P=0.03)， FEV1/FVC (MD=1.43，95%CI=0.00 to 2.85，P=0.05)， pH of arterial blood gas (MD=-0.01， 95%CI=-0.03 to 0.01， P=0.43)， PO2 of arterial blood gas (MD=-3.97， 95%CI=-7.41 to 15.35，P=0.49)， PCO2 of arterial blood gas (MD=0.94，95%CI=-2.69，4.57，P=0.61)，(MD=-0.94，95%CI=-0.23 to 0.04，P=0.19). Funnel plot of the remission rate of clinical signs and incidence of adverse reactions were asymmetric，which indicated publication bias. ConclusionMagnesium sulfate of intravenous infusion could significantly improve the FEV1% of lung function of COPD patients. Furthermore， it could improve the remission rate of clinical signs and have a lower incidence of adverse reaction. But there is no significant difference with other indicators. Due to limited quantity and quality of the included studies， the conclusion above should be further verified by conducting more high quality， large scale， multicentre RCTs.

Key words: pulmonary disease, chronic obstructive；magnesium sulfate, metaanalysis